The European advisory group CHMP has adopted a positive opinion recommending approval of Eli Lilly’s (NYSE:LLY) Baqsimi (glucagon) for severe hypoglycemia (low blood sugar).
The product is administered through the nose via a
single-use dispenser. The recipient does not have to inhale or breathe
deeply after dosing, enabling delivery even in someone unconscious.
Other glucagons are administered via injection.
A final decision from the European Commission usually takes ~60 days.
https://seekingalpha.com/news/3506826-european-advisory-group-backs-lillys-nasally-administered-glucagon
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.